The efficacy rate of China’s CanSinoBIOs’ single-dose COVID-19 vaccine may decrease by 50% in six months after administration.
During an online presentation on Wednesday, the Chief Scientific Officer (CSO) of CanSinoBIO, Zhu Tao, said that a second dose of the vaccine after six months could increase the immunity by seven to ten times.
According to CSO CanSinoBIO, the booster shot administered six months later can take the efficacy rate beyond 90%.
Known as Ad5-nCoV, CanSinoBIO developed the Coronavirus vaccine in collaboration with the Beijing Institute of Biotechnology and tested it in large-scale phase-III clinical trials that were held in five countries, including Pakistan, in which more than 40,000 volunteers participated.
Results of trials were published in February which confirmed that the CanSinoBIO vaccine was 65% effective at preventing symptomatic cases and 91% effective at preventing severe infection.
As for the Pakistani subset, the vaccine offered 75% protection against symptomatic cases and 100% protection against severe infection.
CanSinoBIO is one of the main suppliers of Coronavirus vaccines to Pakistan. The Chinese vaccine has been approved for use in China, Pakistan, Hungary, and Mexico.
The Chinese vaccine manufacture is also planning to hold clinical trials to determine the safety, efficacy, and immunogenicity of the inhaled version of its COVID-19 vaccine.